HomeCompareNAV vs ABBV

NAV vs ABBV: Dividend Comparison 2026

NAV yields 541.87% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NAV wins by $114979.12M in total portfolio value
10 years
NAV
NAV
● Live price
541.87%
Share price
$44.50
Annual div
$241.13
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$114979.22M
Annual income
$84,355,398,966.77
Full NAV calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NAV vs ABBV

📍 NAV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNAVABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NAV + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NAV pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NAV
Annual income on $10K today (after 15% tax)
$46,058.54/yr
After 10yr DRIP, annual income (after tax)
$71,702,089,121.75/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NAV beats the other by $71,702,068,065.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NAV + ABBV for your $10,000?

NAV: 50%ABBV: 50%
100% ABBV50/50100% NAV
Portfolio after 10yr
$57489.66M
Annual income
$42,177,711,869.27/yr
Blended yield
73.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NAV
Analyst Ratings
8
Buy
19
Hold
5
Sell
Consensus: Hold
Price Target
$20.00
-55.1% upside vs current
Range: $20.00 — $20.00
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NAV buys
0
ABBV buys
0
No recent congressional trades found for NAV or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNAVABBV
Forward yield541.87%3.06%
Annual dividend / share$241.13$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$114979.22M$102.3K
Annual income after 10y$84,355,398,966.77$24,771.77
Total dividends collected$112366.23M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$20.00$256.15

Year-by-year: NAV vs ABBV ($10,000, DRIP)

YearNAV PortfolioNAV Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$64,887$54,186.52$11,550$430.00+$53.3KNAV
2$398,024$328,595.73$13,472$627.96+$384.6KNAV
3$2,309,679$1,883,793.41$15,906$926.08+$2.29MNAV
4$12,687,609$10,216,252.22$19,071$1,382.55+$12.67MNAV
5$66,024,585$52,448,843.61$23,302$2,095.81+$66.00MNAV
6$325,727,259$255,080,952.36$29,150$3,237.93+$325.70MNAV
7$1,524,623,898$1,176,095,730.75$37,536$5,121.41+$1524.59MNAV
8$6,776,135,933$5,144,788,362.32$50,079$8,338.38+$6776.09MNAV
9$28,620,396,614$21,369,931,165.66$69,753$14,065.80+$28620.33MNAV
10$114,979,223,344$84,355,398,966.77$102,337$24,771.77+$114979.12MNAV

NAV vs ABBV: Complete Analysis 2026

NAVStock

Navistar International Corporation, through its subsidiaries, manufactures and sells commercial trucks, diesel engines, school and commercial buses, and service parts for trucks and diesel engines worldwide. The company operates through four segments: Truck, Parts, Global Operations, and Financial Services. It manufactures and distributes Class 4 through 8 trucks and buses in the common carrier, private carrier, government, leasing, construction, energy/petroleum, and student and commercial transportation markets under the International and IC brands; and designs, engineers, and produces sheet metal components, including truck cabs and engines. The company also provides customers with proprietary products needed to support the International commercial truck, IC bus, and engine lines, as well as other product lines; and a selection of other standard truck, trailer, and engine aftermarket parts. In addition, it manufactures and distributes mid-range diesel engines, as well as provides customers with additional engine offerings in the agriculture, marine, genset, and light truck markets; sells engines to original equipment manufacturers (OEM) for various on-and-off-road applications; and offers contract manufacturing services under the MWM brand to OEMs for the assembly of their engines. Further, the company provides retail, wholesale, and lease financing of products of its trucks and parts, as well as financing for wholesale and retail accounts receivable. Additionally, it offers military parts and chasis. The company markets its commercial products through an independent dealer network, as well as through retail outlets; and its reconditioned used trucks to owner-operators and fleet buyers through its network of used truck dealers. It operates approximately 1,052 outlets in the United States and Canada, and 89 outlets in Mexico. Navistar International Corporation was founded in 1902 and is headquartered in Lisle, Illinois.

Full NAV Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NAV vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NAV vs SCHDNAV vs JEPINAV vs ONAV vs KONAV vs MAINNAV vs JNJNAV vs MRKNAV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.